Despite inherent differences, Snakebite Envenoming and COVID- 19 have much in common in terms of research and development (R&D) challenges and opportunities. Both crises require a diversified portfolio of R&D solutions, ranging from diagnostics to treatments, that can effectively work and be accessible in different resource settings. Collaborative clinical research and streamlined regulatory pathways are critical to accelerate these candidates in the R&D pipeline. Transformative progress is possible with a concerted approach that aligns strong political will, coordinated financing and the needs of the most marginalised communities.